280 related articles for article (PubMed ID: 20504250)
1. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
5. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
7. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
[TBL] [Abstract][Full Text] [Related]
8. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
[TBL] [Abstract][Full Text] [Related]
9. [Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
Garajová I; Svoboda M; Slabý O; Kocáková I; Fabian P; Kocák I; Vyzula R
Klin Onkol; 2008; 21(6):330-7. PubMed ID: 19382596
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
Kim JS; Kim JM; Li S; Yoon WH; Song KS; Kim KH; Yeo SG; Nam JS; Cho MJ
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):195-200. PubMed ID: 16839708
[TBL] [Abstract][Full Text] [Related]
12. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
15. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
[TBL] [Abstract][Full Text] [Related]
16. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E; Agostini M; Pucciarelli S; De Paoli A; Canzonieri V; Sigon R; De Mattia E; Friso ML; Biason P; Visentin M; Nitti D; Toffoli G
Pharmacogenomics J; 2011 Jun; 11(3):214-26. PubMed ID: 20368715
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
[TBL] [Abstract][Full Text] [Related]
18. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
Soumarova R; Skrovina M; Bartos J; Gruna J; Wendrinski A; Czudek S; Kycina R; Parvez J
Eur J Surg Oncol; 2010 Mar; 36(3):251-6. PubMed ID: 19879716
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
Páez D; Paré L; Altés A; Sancho-Poch FJ; Petriz L; Garriga J; Monill JM; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1681-9. PubMed ID: 20165956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]